Pentixapharm Holding AG (XETRA:PTP.DE)
| Market Cap | 945.00K+6.5% |
| Revenue (ttm) | 242.00K |
| Net Income | -15.03M |
| EPS | -0.58 |
| Shares Out | 500.00K |
| PE Ratio | n/a |
| Forward PE | -2.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 822 |
| Open | 1.86 |
| Previous Close | 1.84 |
| Day's Range | 1.86 - 1.89 |
| 52-Week Range | 1.30 - 3.70 |
| Beta | 1.46 |
| Analysts | none |
| Price Target | 9.27(+390.21%) |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About PTP.DE
Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for functional adrenal tumors, which is in Phase II study. It also develops anti-GlycoTarget antibodies to treat solid tumors. In addition, the company's PentixaFor is being developed as a diagnostic tool for primary hypertension, a cause of hypertension, which is in Phase III trial. Further, its pipeline products for oncology indications include PT-00X, GT-00X, GT-001, GT-002, GT-005, and GT-008. Pentixapharm Holding AG was founded in 2019 and is based in Berlin, Germany.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$PTP.DE stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in PTP.DE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PTP.DE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PTP.DE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PTP.DE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PTP.DE from public contracts
Source: USAspending.gov
PTP.DE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from PTP.DE’s recent data — informational, not investment advice